Get the app
public
ios_share
OncLive® On Air
chevron_right
S11 Ep8: Salgia Summarizes the Benefits of Tepotinib in MET Exon 14–Mutated NSCLC
Sep 2, 2024
12:55
forum
Ask episode
play_arrow
Play
view_agenda
Chapters
auto_awesome
Transcript
info_circle
Episode notes
Dr Salgia discusses how he chooses between tepotinib and capmatinib in patients with stage IV NSCLC harboring MET exon 14 skipping mutations.
OncLive® On Air OncLive® On Air OncLive® On Air